Sildalis
In brief
- In some online pharmacies and unregulated suppliers Sildalis can be bought without a prescription or receipt; it is commonly sold over the internet rather than through official, registered pharmacy supply chains and is not registered with major regulators.
- Sildalis is used for erectile dysfunction; it combines sildenafil and tadalafil, both phosphodiesterase type 5 (PDE5) inhibitors that increase cGMP in penile tissue, causing smooth muscle relaxation and increased blood flow to produce an erection.
- The usual dose is one tablet containing 100 mg sildenafil + 20 mg tadalafil, taken about 30–60 minutes before sexual activity, not more than one tablet in 24 hours.
- The form of administration is an oral tablet (red, oval tablets typically supplied in blister packs).
- The effect usually begins within 30–60 minutes after ingestion.
- Duration of action: sildenafil typically lasts about 4–6 hours while tadalafil can last up to 36 hours; the combination may provide both an immediate effect and a prolonged window of activity, though the safety and exact pharmacokinetics of the combo are not well established.
- Alcohol warning: avoid excessive alcohol as it can increase dizziness, fainting and other side effects and may reduce the drug’s effectiveness.
- The most common side effect is headache.
- Would you like to try sildalis without a prescription?
Sildalis: What Australian Patients Need To Know
Basic Sildalis Information
- INN (International Nonproprietary Name): Sildalis does not have an official INN; it is a combination medication containing sildenafil citrate (INN: sildenafil) and tadalafil (INN: tadalafil).
- Brand Names Available In Australia: Sildalis is marketed as a non-innovator, mostly internet-sold combination drug and is primarily available through online pharmacies and unofficial distributors rather than registered local pharmacies.
- ATC Code: G04BE03 (sildenafil) and G04BE08 (tadalafil).
- Forms & Dosages: Sildalis is sold as tablets containing 100mg sildenafil + 20mg tadalafil in blisters of 6–20.
- Manufacturers In Australia: Not produced by major originators in Australia; manufacturing is mostly by Indian generic companies and direct-to-web suppliers.
- Registration Status In Australia: Not registered with major national drug agencies as a combination product.
- OTC / Rx Classification: Prescription only in regulated jurisdictions, but commonly sold without prescription via online shops operating outside regulated supply chains.
Neueste Research Findings (2022–2025)
Are there good trials proving a fixed sildenafil+tadalafil pill works better than single drugs?
Current Austrian and EU evidence does not support formal approval or a robust randomised controlled trial programme for a fixed sildenafil+tadalafil combination.
Large, high‑quality trials published 2022–2025 focus on monotherapy, with sildenafil and tadalafil separately showing established efficacy for erectile dysfunction.
Tadalafil additionally has EMA‑labelled uses for benign prostatic hyperplasia and, in other formulations/doses, for pulmonary arterial hypertension.
Pharmacovigilance summaries from EU databases and national reports show sporadic adverse event signals linked to online‑sourced, unregulated ED products, including hypotension, priapism and visual disturbances, but causality for combination products is poorly characterised.
Austrian clinical registries contain no approvals listed for combined sildenafil+tadalafil products, so clinicians extrapolate efficacy and safety from monotherapy data and warn about additive adverse effects.
| Study Type | Population | Key Outcome |
|---|---|---|
| Randomised Controlled Trials (monotherapy) | Men With Erectile Dysfunction (various ages) | Sildenafil and tadalafil each show statistically significant improvement in IIEF scores versus placebo. |
| Observational Pharmacovigilance Reports | EU And National Reporting Systems | Sporadic reports of hypotension, priapism and visual disturbances linked to unregulated online ED products. |
| National Registry Reviews (Austria) | Clinical Prescribing Records | No registry listings or approvals for a fixed sildenafil+tadalafil combination product. |
Data highlights: no public regulatory record of an approved fixed‑dose sildenafil+tadalafil product; published evidence 2022–2025 supports monotherapy effectiveness and safety profiles for each PDE5 inhibitor individually.
Clinical keyword context includes sildenafil, tadalafil and combination therapy in ED trials; regulatory status and pharmacovigilance remain the main concerns for combined formulations.
Clinical Effectiveness In Austria
What outcomes do Austrian clinicians measure when treating ED?
Endpoints used in routine care include validated erectile function scores, safety markers and patient‑reported satisfaction.
- International Index of Erectile Function (IIEF) score: assesses erectile function domains.
- Safety markers: blood pressure changes, syncope, priapism incidence and visual disturbances.
- Patient‑reported outcomes: sexual confidence, partner satisfaction and adverse effect burden.
There are no national, peer‑reviewed RCTs in Austria proving added benefit of concurrent sildenafil + tadalafil dosing.
Sildalis is primarily available through online pharmacies and unofficial distributors and is not registered with major agencies, implying no formal Austrian efficacy datasets for the fixed combination.
Austrian outpatient practice records outcomes through e‑Medikation and electronic GP and urology notes, which do not list a registered combination product.
Clinicians therefore use validated tools such as IIEF scores and cardiovascular risk stratification before prescribing licensed agents.
Some anecdotal reports and private practice notes suggest perceived “enhanced potency” from combination use, but objective measures and safety endpoints for the combination are inadequately documented.
When presenting local data, the following outcome measures are most useful: IIEF change from baseline, systolic/diastolic blood pressure change, incidence of priapism and rate of treatment discontinuation due to adverse effects.
Indications And Off‑Label Use
Which conditions are officially approved for sildenafil and tadalafil, and where does the combination sit?
| Product | EMA‑labelled Uses | Notes |
|---|---|---|
| Sildenafil (Viagra®) | Erectile Dysfunction | Well established for on‑demand use in ED. |
| Tadalafil (Cialis®) | Erectile Dysfunction; BPH; PAH (different formulations) | Longer duration supports once‑daily or as‑needed regimens depending on indication. |
| Sildalis (fixed combo) | None officially | Not registered; no EMA or national approval for a combined product. |
Approved indications are covered by licensed monotherapy products and follow EMA guidance.
Off‑label combination of PDE5 inhibitors is uncommon and generally discouraged because additive systemic vasodilation increases cardiovascular risk.
Rare specialist‑managed off‑label scenarios may exist for refractory ED under tight monitoring, but these are exceptions and not standard care.
Clinicians should rely on established monotherapy indications and avoid routine use of unregistered combination products.
Composition And Brand Landscape
What exactly is in Sildalis and who makes it?
| Brand Name | Active Ingredients | Strengths | Packaging |
|---|---|---|---|
| Sildalis | Sildenafil + Tadalafil | 100mg sildenafil + 20mg tadalafil | Blisters of 6–20 |
Sildalis is described as a non‑innovator combination tablet, often red and oval, and commonly labelled in English or Russian on internet listings.
Manufacture is mostly by Indian generic companies such as RSM Enterprises and Sunrise Remedies or other direct‑to‑web suppliers.
In Austria, authorised alternatives are single‑agent sildenafil (Viagra® and generics) and tadalafil (Cialis® and generics), and other licensed products for PAH such as Adcirca where relevant.
No major originator companies (Pfizer, Eli Lilly) produce a combined sildenafil+tadalafil product for registered markets.
Pharmacy staff should be aware of the packaging differences and the absence of regulatory approval for combined formulations when counselling patients.
Contraindications And Precautions
Who must not take Sildalis or should use extreme caution?
- Absolute Contraindications: known allergy to sildenafil or tadalafil, concomitant use with nitrates (including nitroglycerin), co‑administration with riociguat, and severe cardiovascular disease that precludes sexual activity.
- Relative Precautions: significant hepatic or renal impairment, recent stroke or myocardial infarction, unstable angina, heart failure and retinitis pigmentosa.
Concomitant nitrates or riociguat can produce life‑threatening hypotension and must never be combined with PDE5 inhibitors.
Patients with multiple antihypertensives, alpha‑blockers or other vasodilators require careful review because additive blood pressure lowering can cause syncope.
Pharmacists in Austria should flag prescriptions that conflict with e‑medikation records, especially nitrates, and counsel patients to seek medical review if uncertain.
Activities requiring full alertness, such as driving or operating heavy machinery, should be avoided if the patient experiences dizziness or visual disturbances after dosing.
Dosing Guidance And Adjustments
How should Sildalis be taken if a patient still chooses to use it?
Typical marketed Sildalis strength is 100mg sildenafil + 20mg tadalafil and the stated dosing guidance is one tablet taken about 30–60 minutes before anticipated sexual activity, not more than once per 24 hours.
This fixed high dose combines a common on‑demand sildenafil dose with a typical tadalafil on‑demand dose, which increases the likelihood of additive adverse effects such as hypotension.
There are no formal pharmacokinetic or dose‑finding studies for the combination, so dose adjustments are not established for the fixed product.
- Children: not approved or recommended.
- Elderly: start at the lowest effective dose for the individual PDE5 inhibitor and monitor for hypotension and other adverse effects.
- Liver or kidney impairment: reduce starting doses for sildenafil and tadalafil individually; no specific guidance exists for the fixed combination.
A conservative clinical approach is to avoid the combination unless supervised by a specialist who can monitor cardiovascular status and adverse events.
Emergency instructions: in overdose or priapism, seek emergency care immediately; management is symptomatic and supportive.
Overview Of Interactions
Which drugs and foods interact with sildenafil and tadalafil?
| Interacting Agent | Severity | Mechanism / Note |
|---|---|---|
| Nitrates (nitroglycerin) | Absolute Contraindication | Profound hypotension when combined with PDE5 inhibitors. |
| Riociguat | Absolute Contraindication | Severe hypotension risk. |
| Strong CYP3A4 Inhibitors (ritonavir, ketoconazole) | High | Increase sildenafil/tadalafil plasma levels, raising adverse event risk. |
| Alpha‑Blockers / Antihypertensives | Moderate | May cause additive blood pressure lowering; dose spacing and monitoring advised. |
| Grapefruit Juice | Moderate | Can affect CYP3A4‑metabolised drugs and potentially increase exposure. |
| Alcohol | Moderate | Increases orthostatic hypotension risk and may worsen dizziness. |
Pharmacists should check e‑medikation / e‑card records for nitrates, riociguat, protease inhibitors, strong antifungals and multiple antihypertensives before supply.
An interaction checklist for the pharmacy counter helps: nitrates, riociguat, strong CYP3A4 inhibitors, alpha‑blockers, antihypertensives, alcohol and grapefruit intake.
Patient Behaviour And Access In Austria
Why do many men buy ED medicines online rather than through the GP or Apotheken?
Stigma and desire for anonymity drive many patients to online suppliers and unofficial distributors.
Sildalis is primarily available through online pharmacies and unofficial distributors, which reflects that pattern of anonymous sourcing.
Rural areas with fewer independent Apotheken and longer travel times tend to show higher online sourcing and occasional cross‑border shopping to neighbouring countries such as Germany, Czechia or Hungary.
Urban centres and pharmacy chains offer more private counselling and often have private consultation rooms for discussing sensitive issues.
The national e‑card and e‑medikation system supports prescription continuity but is underused by people who buy medicines via online marketplaces.
Pharmacists should be sensitive to privacy concerns, encourage face‑to‑face risk assessment and explain safety reasons for using licensed products rather than unregistered combinations.
In our online pharmacy, sildalis is available without a prescription, with discreet delivery to Australia in 5-14 days.
Availability, Regulation And Reimbursement
Can patients expect Sildalis to be covered by Sozialversicherung in Austria or sold legally in Apotheken?
Sildalis is not registered with major national agencies and is primarily available via online pharmacies and unofficial distributors rather than registered Apotheken.
In Austria, sildenafil and tadalafil are prescription‑only and dispensed through Apotheken, with reimbursement by Sozialversicherung generally linked to authorised products and documented indications.
An unregistered combination product is unlikely to be covered by Sozialversicherung and may carry legal or safety risks if imported without a valid prescription.
| Product | Typical Online Price | Licensed Pharmacy Price (Austria) | Reimbursement |
|---|---|---|---|
| Sildalis (100/20) | Often lower on unregulated websites | Not available via licensed Apotheken | Unlikely |
| Sildenafil (Viagra® / Generics) | Variable | Available via Apotheken | Possible for documented indications |
| Tadalafil (Cialis® / Generics) | Variable | Available via Apotheken | Possible for documented indications |
Pharmacies and patients should be aware that online prices for unregistered combos may be attractive but carry higher safety and legal risks due to lack of registration and quality assurance.
Importing prescription medicines without an appropriate prescription or approval can create problems at customs and with local reimbursement policies.
Alternatives And Clinical Choices
How should clinicians choose between Viagra, Cialis and other options rather than a fixed combination?
| Option | Pros | Cons |
|---|---|---|
| Sildenafil Monotherapy | Established onset of action for on‑demand dosing, familiar safety profile, widely available generics. | Shorter duration compared with tadalafil. |
| Tadalafil Monotherapy | Longer duration, useful for intermittent activity or BPH symptom control, available generics and branded options. | Longer exposure may prolong adverse effects in susceptible patients. |
| Sildalis (Unapproved Combination) | Marketed claims of “dual action” or enhanced potency. | No regulatory approval, limited safety data, higher theoretical risk of combined vasodilation. |
Therapeutic choice in Austria depends on onset/duration needs, comorbidities, drug interactions and patient preference.
Monotherapy advantages include regulatory oversight, established dosing guidance and a clearer safety profile, while the unapproved combination lacks regulatory evaluation and robust clinical evidence.
Use a clinical decision tree that starts with cardiovascular risk screening, reviews current medications, matches expected sexual activity timing to drug duration, and selects an authorised product accordingly.
Frequently Asked Questions
Q: Is Sildalis legal in Austria?
A: The active ingredients are legal when prescribed, but the fixed product Sildalis is not registered with major agencies and is usually sold online outside regulated supply chains.
Q: Is it safe to take without doctor review?
A: No; medical review is recommended because of contraindications such as nitrates and possible cardiovascular risks.
Q: Will Sozialversicherung reimburse Sildalis?
A: Unlikely; reimbursement generally applies to authorised products with documented indications rather than unregistered combination imports.
Q: What should I do if I experience side effects?
A: Stop dosing and seek urgent care for severe reactions such as syncope, chest pain, sudden vision loss or priapism.
Report adverse reactions to your pharmacy and the national pharmacovigilance system.
Pharmacy Counselling And Austrian Standards
What should pharmacists do at the counter when a patient asks about Sildalis?
Verify the prescription via e‑card and e‑medikation and perform medication reconciliation to check for nitrates, riociguat and interacting medicines.
Assess cardiovascular fitness for sexual activity and counsel on dosing advice: one tablet per 24 hours if using the marketed Sildalis dose, recognising this guidance is not supported by formal combination studies.
Counsel on common side effects such as headache, flushing, nasal congestion, dizziness, visual changes and back pain and advise what to do in emergencies (priapism, syncope).
Advise storage below 30°C and keeping medicines away from children.
Document counselling in the patient record and report any adverse events to the national pharmacovigilance system and Apothekerkammer where appropriate.
Provide short patient leaflets in German and English that explain legal, safety and import risks of unregistered products and list licensed alternatives available via Apotheken.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 5-7 days |
| Melbourne | Victoria | 5-7 days |
| Brisbane | Queensland | 5-7 days |
| Perth | Western Australia | 5-9 days |
| Adelaide | South Australia | 5-7 days |
| Canberra | Australian Capital Territory | 5-7 days |
| Hobart | Tasmania | 5-9 days |
| Darwin | Northern Territory | 5-9 days |
| Gold Coast | Queensland | 5-7 days |
| Newcastle | New South Wales | 5-7 days |
| Wollongong | New South Wales | 5-7 days |
| Geelong | Victoria | 5-7 days |
| Townsville | Queensland | 5-9 days |
| Cairns | Queensland | 5-9 days |
Final Practical Advice For Patients And Pharmacists
If a patient asks for “enhanced potency” pills, explain clearly that Sildalis is an unregistered fixed combination and lacks regulatory safety data.
Offer authorised sildenafil or tadalafil alternatives and discuss onset, duration and side‑effect differences so the patient can choose an evidence‑based option.
Use the IIEF score and a brief cardiovascular checklist to guide safe prescribing and refer to urology when ED is refractory or complex.
Document any counselling or supply decisions in the patient record and report suspected poor‑quality or counterfeit products to the national authorities.
When a patient insists on online imports, explain legal and safety implications and encourage a face‑to‑face review to reconcile medications and assess contraindications.
For pharmacists: keep a quick reference checklist at the counter covering nitrates, riociguat, strong CYP3A4 inhibitors, antihypertensives and guidance for suspected adverse events.
Patients experiencing severe side effects should be advised to seek immediate emergency care and to bring the medicine packaging to assessment for possible product verification.
Licensed monotherapy with sildenafil or tadalafil remains the recommended and regulated approach for most patients.
